EVMN.US Evommune, Inc.

Healthcare Biotechnology USA Stocks
7.63 USD
Close of Nov 14, 2026
4.94 33.20
Market cap
USD 277M
P/E
-
P/B
1.05x
ROE
-38.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is EVMN.US undervalued?

Graham number

The Graham number of Evommune, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Evommune, Inc. fundamental analysis

No fundamental analysis for Evommune, Inc. yet.

Evommune, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Evommune, Inc.

Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alt…

Full company profile